Nephrotic Syndrome Steroid-Dependent Clinical Trial
Official title:
Treatment of Steroid Dependent Idiopathic Nephrotic Syndrome in Children With Low Doses of Interleukin 2: a Pilot Study
NIL-2 is a clinical trial designed to evaluate the efficacy and safety of low doses of Interleukin2 in the treatment of recently diagnosed, steroid dependent idiopathic nephrotic syndrome in children. Recent data suggest that Interleukin 2 could be an effective therapy via an increased production of regulatory T cells.
The study will include 10 children (age: 3-15 years old). Patients will receive low doses of
Interleukin 2 (0.5 million UI/m²/ injection, subcutaneously).
The treatment will be initiated with an induction phase of one injection per day for 5
consecutive days, followed by a maintenance phase in which patients will receive one
injection every 14 days for 6 months.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04585152 -
Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Idiopathic Nephrotic Syndrome.
|
Phase 2 | |
| Terminated |
NCT04402580 -
Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome
|
Phase 2 |